🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Redeye comments on Safello announcing a partnership with Marginalen Bank, positioning itself as the first crypto broker to offer a comprehensive suite of banking services to its customers. $SFL redeye.se/research/11207…

Redeye has interviewed Physitrack’s CEO following a strong Q2 marked by margin expansion and positive free cash flow. $PTRK redeye.se/research/11207…

Redeye provides an update on NextCell following the company’s Q3 report, which came in largely in line with expectations. $NXTCL redeye.se/research/11190…

Redeye notes that Gapwaves' Q2 2025 report exceeded its estimates on all key metrics. $GAPW redeye.se/research/11207…

Redeye is happy to see OXE Marine beating our forecasts across the board. Sales grew by 35% Y/Y and gross margins improved to 37%. $OXE redeye.se/research/11208…

Redeye comments on the outcome of AlzeCure’s rights issue, which was significantly oversubscribed at 212%, raising net SEK55.5m. $ALZCUR redeye.se/research/11207…

Redeye provides a comment on DalaVind’s divestment of Fageråsen, an onshore wind project of more than 200MW, to OX2. $DE redeye.se/research/11208…

Redeye returns with revised estimates following Polygiene's Q2 2025 report, which was on the weak side, mainly driven by weak sales for Addmaster $POLYG redeye.se/research/11195…

Redeye states that Gapwaves delivered a solid report with beats across key metrics. $GAPW redeye.se/research/11208…

Redeye makes rather small, but positive, changes to our financial forecasts on the back of Oxe Marine's strong Q2 numbers. $OXE redeye.se/research/11209…

Redeye comments on Physitrack delivering a solid Q2, highlighted by margin expansion, positive free cash flow, and greater operational efficiency. $PTRK redeye.se/research/11209…

Redeye updates its forecast and valuation following Modelon’s Q2 2025 report, which came broadly in line with expectations despite currency headwinds and softer solution services. $MODEL redeye.se/research/11169…

Redeye provides a short comment on the recently announced directed issue from Scandinavian ChemoTech. $CMOTEC redeye.se/research/11210…

Redeye har intervjuat AlzeCures vd Martin Jönsson om det starka utfallet i företrädesemissionen och om bolagets prioriteringar framåt. $ALZCUR redeye.se/research/11208…

Arise is trading below Redeye's Base Case. We spoke with Redeye's analyst about Arise's segment strategy, the Kölvallen project and more. This is a premium article, included in our paid plans from SEK 99/month. $ARISE redeye.se/research/11210…

Redeye comments on today’s news from Thunderful Group, which includes a SEK50m directed share issue, a CEO change, and a restructuring program. $THUNDR redeye.se/research/11211…

Redeye comments on XVIVO's delayed launch being a setback for both XVIVO, patients and specialist centers waiting to use the solution. $XVIVO redeye.se/research/11211…

Redeye views the recently announced progress on US reimbursements positively, as a second payor has agreed to provide a fixed reimbursement of USD300 for the CADScor System. $ACARIX redeye.se/research/11211…

Redeye comments on the partnership with SD Pharma in Spain, which will broaden physician reach of Pepaxti. $ONCO redeye.se/research/11211…

Redeye comments on GiG’s preliminary Q2-results which were in line with our forecasts and the announcement of a directed share issue expected to raise around EUR22m. $GIG redeye.se/research/11211…